机译:依托珠单抗奥佐米星(CMC-544)在以利妥昔单抗为基础治疗的日本滤泡性淋巴瘤患者中的I期研究
Department of Hematology and Oncology, Nagoya Daini Red Cross Hospital, Nagoya;
Hematology and Stem Cell Transplantation Division, National Cancer Center Hospital, Tokyo;
Department of Hematology, Cancer Institute Hospital, Tokyo;
Department of Hematology and Oncology, Nagoya Daini Red Cross Hospital, Nagoya;
Department of Hematology and Oncology, Nagoya Daini Red Cross Hospital, Nagoya;
Department of Hematology and Oncology, Nagoya Daini Red Cross Hospital, Nagoya;
Department of Hematology and Oncology, Nagoya Daini Red Cross Hospital, Nagoya;
Hematology and Stem Cell Transplantation Division, National Cancer Center Hospital, Tokyo;
Hematology and Stem Cell Transplantation Division, National Cancer Center Hospital, Tokyo;
Hematology and Stem Cell Transplantation Division, National Cancer Center Hospital, Tokyo;
Hematology and Stem Cell Transplantation Division, National Cancer Center Hospital;
机译:在以利妥昔单抗为基础治疗的日本滤泡性淋巴瘤患者中,inotozumab ozogamicin(CMC-544)的I期研究。
机译:在以利妥昔单抗为基础治疗的日本滤泡性淋巴瘤患者中,inotozumab ozogamicin(CMC-544)的I期研究。
机译:依托珠单抗ozogamicin(CMC-544)在以利妥昔单抗为基础治疗的日本滤泡性淋巴瘤患者中的I期研究
机译:鉴定卵腔淋巴瘤患者总生存的基因重要性
机译:免疫调节药物来那度胺在淋巴瘤患者中的安全性和有效性:RU051417I-R-ICE(利妥昔单抗-异环磷酰胺-卡铂-依托泊苷)与来那度胺[R2-ICE]的I / II期开放标签研究的进展初次复发/原发性难治性弥漫性大B细胞淋巴瘤(DLBCL)。
机译:两种基于抗体的靶向药物联合治疗非霍奇金淋巴瘤的安全性和临床活性:I / II期研究评估免疫偶联物伊妥珠单抗与利妥昔单抗的临床研究结果
机译:用Rituximab疗法预处理日本卵泡淋巴瘤患者Inotuzumab ozogamicin(CMC-544)的研究